27.1  0.25 (0.93%)		04-10 16:00
Open: 26.775 High: 28 Volume: 10,125		Pre. Close: 26.85 Low: 26.1574 Market Cap: 1,189(M)

Short term
Mid term
Targets	6-month :	32.7	1-year :	38.19
Resists	First :	28	Second :	32.7
Pivot price	25.11
Supports	First :	23.11	Second :	20.1
MAs	MA(5) :	26.88	MA(20) :	24.15
	MA(100) :	27.37	MA(250) :	27.78
MACD	MACD :	0.8	Signal :	0.3
%K %D	K(14,3) :	86.3	D(3) :	87
RSI	RSI(14): 60.7
52-week	High :	55.65	Low :	5.98

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ NNNN ] has closed below upper band by 18.0%. Bollinger Bands are 48.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	28.01 - 28.15	28.15 - 28.29
Low:	25.85 - 25.98	25.98 - 26.12
Close:	26.88 - 27.1	27.1 - 27.32

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.

Thu, 09 Apr 2026
Anbio Biotechnology (NNNN) files 20-F/A to mark well-known seasoned issuer - Stock Titan

Tue, 07 Apr 2026
Super-voting control and post-COVID shift at Anbio Biotechnology (Nasdaq: NNNN) - Stock Titan

Tue, 27 Jan 2026
Anbio Biotechnology (NNNN) Stock Price, News & Analysis - MarketBeat

Mon, 28 Apr 2025
NNNN Stock Price, News & Analysis - Stock Titan

Fri, 21 Feb 2025
Anbio Biotechnology Class A Ordinary Shares (NNNN) Stock Forecast & Price Prediction 2026–2030 - CoinCodex

Thu, 20 Feb 2025
Anbio Biotechnology Announces Closing of Initial Public Offering - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	44 (M)
Shares Float	40 (M)
Held by Insiders	4.7 (%)
Held by Institutions	4.8 (%)
Shares Short	36 (K)
Shares Short P.Month	52 (K)

EPS	0.05
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.62
Profit Margin	37.2 %
Operating Margin	73.4 %
Return on Assets (ttm)	4.7 %
Return on Equity (ttm)	11.1 %
Qtrly Rev. Growth	-21.7 %
Gross Profit (p.s.)	0.14
Sales Per Share	0.15
EBITDA (p.s.)	0
Qtrly Earnings Growth	2.7 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	451.66
PEG Ratio	0
Price to Book value	43.01
Price to Sales	171.88
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.